--- title: "Alnylam Pharmaceuticals (NasdaqGS:ALNY) Sees 17% Weekly Gain As Vutrisiran Faces FDA Decision" description: "Alnylam Pharmaceuticals (NasdaqGS:ALNY) experienced a 17% weekly gain, driven by recent announcements and market trends, including the upcoming FDA decision on Vutrisiran. The company's strong R&D pip" type: "news" locale: "en" url: "https://longbridge.com/en/news/232868924.md" published_at: "2025-03-23T18:51:14.000Z" --- # Alnylam Pharmaceuticals (NasdaqGS:ALNY) Sees 17% Weekly Gain As Vutrisiran Faces FDA Decision > Alnylam Pharmaceuticals (NasdaqGS:ALNY) experienced a 17% weekly gain, driven by recent announcements and market trends, including the upcoming FDA decision on Vutrisiran. The company's strong R&D pipeline and strategic partnerships, such as with Roche, bolster investor confidence. Despite recent losses from development costs, Alnylam's total revenues are projected between US$2.05 billion and US$2.25 billion for 2025, reflecting a total return of 171.92% since early 2020. The retirement of co-founder Dr. Phillip A. Sharp may signal a leadership shift while maintaining continuity. Alnylam Pharmaceuticals (NasdaqGS:ALNY) saw a 17% price increase over the past week, likely influenced by its recent announcements and market trends. The company's R&D progress showcase on February 25, featuring innovations like Nucresiran's high TTR knockdown capability and Vutrisiran's impending FDA decision, highlighted its strong pipeline, potentially boosting investor confidence. Additionally, the retirement announcement of co-founder Dr. Phillip A. Sharp on March 5 may have emphasized a shift in leadership while maintaining continuity in its advisory board. Meanwhile, an uptick in major indexes, like the Nasdaq's recent rise, may have also supported Alnylam's positive market performance. Buy, Hold or Sell Alnylam Pharmaceuticals? View our complete analysis and fair value estimate and you decide. The end of cancer? These 22 emerging AI stocks are developing tech that will allow early idenification of life changing disesaes like cancer and Alzheimer's. \`\`\`html Since early 2020, Alnylam Pharmaceuticals has delivered a total return of 171.92%, reflecting a profound impact from its R&D progress and strategic endeavors. Notable achievements include the FDA approval of Vutrisiran for ATTR amyloidosis with cardiomyopathy and the anticipated approval of AMVUTTRA. These approvals are poised to transform the TTR franchise, significantly boosting anticipated revenue. With strategic partnerships, such as the collaboration with Roche for zilebesiran, Alnylam continues to enhance its therapeutic pipeline, underlining its potential for revenue growth despite pressure from competition and the intricacies of payer policy negotiations. Alnylam's financial results show an increase in total revenues with 2025 expectations ranging between US$2.05 billion and US$2.25 billion. The collaboration with Medison Pharma has broadened the availability of its therapies in Central & Eastern Europe and Israel, reinforcing revenue streams. Additionally, expanded partnerships augur well for sustainable innovation. Despite recent losses due to development costs, surpassing both the US market and the Biotechs industry indicates resilient investor confidence in Alnylam's strategic direction. \`\`\` Learn about Alnylam Pharmaceuticals' future growth trajectory here. *This article by Simply Wall St is general in nature. **We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.** It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.* If you're looking to trade Alnylam Pharmaceuticals, open an account with the lowest-cost platform trusted by professionals, Interactive Brokers. With clients in over 200 countries and territories, and access to 160 markets, IBKR lets you trade stocks, options, futures, forex, bonds and funds from a single integrated account. Enjoy no hidden fees, no account minimums, and FX conversion rates as low as 0.03%, far better than what most brokers offer. Sponsored Content ### Related Stocks - [ALNY.US - Alnylam Pharma](https://longbridge.com/en/quote/ALNY.US.md) ## Related News & Research | Title | Description | URL | |-------|-------------|-----| | Alnylam Pharmaceuticals, Inc.(NasdaqGS:ALNY) added to NASDAQ-100 Index | Alnylam Pharmaceuticals, Inc Added to NASDAQ-100 Index. | [Link](https://longbridge.com/en/news/270482423.md) | | Execution Risks Loom as Alnylam Races to Scale Global Operations for AMVUTTRA and 2030 Growth Ambitions | Alnylam Pharmaceuticals (ALNY) faces significant execution risks as it seeks to expand globally and achieve its 2030 gro | [Link](https://longbridge.com/en/news/275858709.md) | | RISING CANCER RATES AND A PROMISING CANCER TREATMENT | The rising cancer rates among younger Americans, highlighted by the death of actor James Van Der Beek from colorectal ca | [Link](https://longbridge.com/en/news/276298689.md) | | 10:02 ETThe Center for Cancer and Blood Disorders Revolutionizes the Delivery of CAR-T Cancer Treatments for Texas Patients | The Center for Cancer and Blood Disorders has launched a program to deliver CAR-T therapy in community practices across | [Link](https://longbridge.com/en/news/276139832.md) | | Roche Announces Filing Acceptance Of New Drug Application For Giredestrant | Roche has announced that the FDA has accepted its New Drug Application for giredestrant, an investigational oral therapy | [Link](https://longbridge.com/en/news/276417142.md) | --- > **Disclaimer**: This article is for reference only and does not constitute any investment advice.